We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+11.92%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$76.2M
Cap. Flow
% of AUM
-39.78%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
D.R. Horton
DHI
|
+$888K |
| 2 |
Lennar Class A
LEN
|
+$880K |
| 3 |
Microchip Technology
MCHP
|
+$860K |
| 4 |
Ametek
AME
|
+$859K |
| 5 |
Home Depot
HD
|
+$853K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steel Dynamics
STLD
|
+$1.62M |
| 2 |
Cheniere Energy
CQP
|
+$1.53M |
| 3 |
STOR
STORE Capital Corporation
STOR
|
+$1.44M |
| 4 |
NOA
North American Construction
NOA
|
+$1.43M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Vaxcyte
PCVX
$7.65B
| $147K | 0.08% |
3,064
-2,846
| -48% | -$112K |
|
352
Viridian Therapeutics
VRDN
$2.2B
| $147K | 0.08% |
+5,017
| New | +$116K |
|
353
Prothena Corp
PRTA
$448M
| $146K | 0.08% |
2,416
-2,141
| -47% | -$125K |
|
|
MRTX
354
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $145K | 0.08% |
3,203
+1,214
| +61% | +$78.6K |
|
355
Syndax Pharmaceuticals
SNDX
$1.7B
| $145K | 0.08% |
5,701
-927
| -14% | -$21.6K |
|
356
Geron
GERN
$898M
| $144K | 0.08% |
59,604
-22,009
| -27% | -$49.3K |
|
357
Krystal Biotech
KRYS
$10.7B
| $143K | 0.07% |
1,804
-267
| -13% | -$19.8K |
|
358
Xenon Pharmaceuticals
XENE
$6.1B
| $143K | 0.07% |
3,616
-57
| -2% | -$2.08K |
|
|
CINC
359
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $142K | 0.07% |
+11,557
| New | +$275K |
|
|
RXDX
360
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $142K | 0.07% |
1,289
-2,895
| -69% | -$188K |
|
|
EQRX
361
DELISTED
EQRx, Inc. Common Stock
EQRX
| $141K | 0.07% |
57,405
+29,911
| +109% | +$118K |
|
362
Zentalis Pharmaceuticals
ZNTL
$332M
| $141K | 0.07% |
7,010
+2,191
| +45% | +$47.1K |
|
363
Pliant Therapeutics
PLRX
$65M
| $141K | 0.07% |
+7,303
| New | +$153K |
|
364
ALX Oncology
ALXO
$262M
| $141K | 0.07% |
12,484
-3,272
| -21% | -$36.8K |
|
|
IMGO
365
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $140K | 0.07% |
3,904
-4,285
| -52% | -$107K |
|
366
AbCellera Biologics
ABCL
$1.65B
| $140K | 0.07% |
13,827
+1,951
| +16% | +$22.5K |
|
|
DAWN
367
DELISTED
Day One Biopharmaceuticals
DAWN
| $139K | 0.07% |
6,482
-119
| -2% | -$2.44K |
|
368
CION Investment
CION
$297M
| $139K | 0.07% |
14,304
+1,661
| +13% | +$16.1K |
|
|
RPTX
369
DELISTED
Repare Therapeutics
RPTX
| $139K | 0.07% |
9,426
+1,789
| +23% | +$26.8K |
|
370
Alector
ALEC
$169M
| $138K | 0.07% |
14,933
+1,938
| +15% | +$16.9K |
|
371
Kodiak Sciences
KOD
$2.5B
| $138K | 0.07% |
19,214
+4,659
| +32% | +$33.4K |
|
372
Revolution Medicines
RVMD
$38.5B
| $137K | 0.07% |
5,771
-443
| -7% | -$9.42K |
|
373
Vir Biotechnology
VIR
$1.46B
| $137K | 0.07% |
5,408
+713
| +15% | +$17.5K |
|
|
KZR
374
DELISTED
Kezar Life Sciences
KZR
| $137K | 0.07% |
1,943
-271
| -12% | -$20.1K |
|
375
Lyell Immunopharma
LYEL
$318M
| $137K | 0.07% |
1,967
+811
| +70% | +$80.6K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2022 Portfolio in Review
As of Q4 2022, Virtus ETF Advisers held 489 positions worth $191M, down 24% from $251M the previous quarter. Its ten largest holdings account for 5.8% of the portfolio.
Virtus ETF Advisers withdrew a net $76.2M in Q4 2022, closing 46 positions and reducing 226 holdings. Its most notable exit was iShares JPMorgan USD Emerging Markets Bond ETF, an estimated $877K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 19% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in D.R. Horton worth $987K.
- Virtus ETF Advisers's largest Q4 2022 buy was D.R. Horton: 11,078 shares worth $987K.
- Virtus ETF Advisers added most to Qualcomm in Q4 2022, an estimated $271K increase.
- Virtus ETF Advisers's biggest Q4 2022 reduction was Steel Dynamics, cutting an estimated $1.62M.
- Virtus ETF Advisers fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q4 2022, selling an estimated $877K.
- Virtus ETF Advisers's ten largest holdings make up 5.8% of its $191M portfolio in Q4 2022.
- Virtus ETF Advisers opened 53 new positions and closed 46 in Q4 2022.
- Virtus ETF Advisers's portfolio value fell 24% quarter-over-quarter to $191M.
Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.